Partnership leverage Explore strategic partnerships with OmniaBio for scalable CARTISTEM manufacturing capacity and GMP testing solutions to accelerate late-stage development in the US and Japan.

Late-stage US opportunity Target US-based osteoarthritis and cartilage defect programs that could benefit from CARTISTEM and related Israel/Canada-sourced manufacturing capabilities, leveraging MEDIPOST's readiness for late-stage trials.

Global commercialization Position to support exclusive or co-commercial licenses in key markets (Japan via Teikoku Seiyaku, Korea, US) to maximize CARTISTEM penetration in knee osteoarthritis and inflammatory cartilage conditions.

Development financing Engage with MEDIPOST on potential milestone-based partnerships and funding rounds tied to GMP testing solutions, CDMO scale-up, and international regulatory progress.

Clinical and data collaboration Offer Alliance or CRO/CMO support for late-stage pivotal trials, real-world evidence generation, and advisory services to strengthen competitive positioning against peers in cell therapy for degenerative diseases.